Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer 2023-01-31 21:50
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI 2023-01-20 21:50
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China 2023-01-16 18:00
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting 2022-12-12 21:50
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs 2022-10-31 21:30
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA 2022-10-18 20:50
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline 2022-08-24 20:50
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology 2022-08-18 20:50
CARsgen Appoints Dr. Hua Jiang as Executive Director 2022-08-02 20:50
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 2022-06-06 20:50
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers 2022-05-10 20:50
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer 2022-04-07 23:42
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China 2022-03-23 20:50
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies 2022-03-23 20:50
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China 2022-03-03 21:50
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation 2022-01-17 21:50
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA 2022-01-10 21:50
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting 2021-12-13 20:00
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041 2021-11-22 20:00
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA 2021-11-15 22:10
1 2 3